Skip to main content
. Author manuscript; available in PMC: 2023 Sep 29.
Published in final edited form as: Cell. 2022 Sep 29;185(20):3705–3719.e14. doi: 10.1016/j.cell.2022.09.007

Figure 6. Mucolytic activity of BT is suppressed by ambient xylose.

Figure 6.

(A) Relative expression levels of PULs in BT RNA transcripts sequenced from stool collected from allogeneic mice treated or untreated with meropenem on day 18. Left: PUL identification numbers. Right: enzymatic functional annotations. (B) Relative abundances of monosaccharides of supernatants from stool collected from normal mice and allogeneic mice treated or untreated with meropenem on day 18 measured by IC-MS. (C) Experimental schema of murine GVHD model. (D) PAS staining of histological colon sections collected on day 20. Bar, 100 μm. (E) Mucus thickness on day 20. Data is shown as means ± SEM. (F) Relative abundance of BT on day 20. (G) Correlation analysis of the relative expression levels of PULs in BT RNA transcripts sequenced from stool collected from meropenem-treated allogeneic mice or those with xylose supplementation on day 21. X axis indicates calculated expression levels of PULs in BT RNA transcripts as mean expression levels of meropenem-treated allogeneic mice to allogeneic mice and Y axis indicates calculated expression levels of PULs in BT RNA transcripts as mean expression levels of meropenem-treated allogeneic mice to those with xylose supplementation. (H) Relative expression levels of PULs in BT RNA transcripts. (I) Overall survival. (E-F, I) Data are combined from two independent experiments.